{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:14:16Z","timestamp":1788437656625,"version":"build-2803163510"},"reference-count":0,"publisher":"International Institute of Anticancer Research","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDP"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Background\/Aim: \nAs populations age, more patients aged \u226580 years with metastatic urothelial carcinoma (mUC) require systemic therapy. However, the efficacy and safety of first-line platinum-based chemotherapy (PBC) in octogenarians remain unclear. This study aimed to describe clinical outcomes in patients aged \u226580 years with mUC eligible for PBC.\nPatients and Methods: \nWe retrospectively analyzed 30 patients with mUC who received first-line PBC between 2005 and 2022. Patient characteristics, tumour response, treatment-related adverse events (TRAEs), and survival outcomes were assessed.\nResults: \nThe median age was 83 (range=80-92) years. The bladder and upper urinary tract were the primary tumour site in 17 and 13 patients, respectively. Performance status was 0 or 1 in 15 patients each. Lymph node\u2013only metastasis was present in 18 patients (60%). Regimens included methotrexate, vinblastine, doxorubicin, and cisplatin in six patients and gemcitabine plus platinum in 24; 15 patients received carboplatin. The median number of cycles was three. The objective response and disease control rates were 40% and 76.7%, respectively. Grade \u22653 TRAEs occurred in 23 patients (76.7%), mainly hematologic toxicities (myelosuppression). Dose reduction was required in 21 patients (70%), and treatment was discontinued in 14 (46.7%) because of toxicity or patient preference (7 each). Median progression-free survival and overall survival were 5.2 and 11.3 months, respectively.\nConclusion: \nFirst-line PBC demonstrated measurable anti-tumour activity in eligible patients aged \u226580 years with mUC. However, myelosuppression often necessitated dose reduction or treatment discontinuation. Thus, PBC in this population warrants careful patient selection and proactive toxicity management.<\/jats:p>","DOI":"10.21873\/cdp.10589","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:23:09Z","timestamp":1788434589000},"page":"882-889","source":"Crossref","is-referenced-by-count":0,"title":["Real-world Outcomes of First-line Platinum-based Chemotherapy in Patients Aged 80 Years or Older With Metastatic Urothelial Carcinoma"],"prefix":"10.21873","volume":"6","author":[{"given":"AKINORI","family":"MINATO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KAZUMASA","family":"JOJIMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUTO","family":"TSUBONUMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUI","family":"MIZUSHIMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOSHIHIRO","family":"SUGITA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAKUO","family":"MATSUKAWA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IKKO","family":"TOMISAKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EIJI","family":"KASHIWAGI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"9336","published-online":{"date-parts":[[2026,9,1]]},"container-title":["Cancer Diagnosis &amp; Prognosis"],"original-title":[],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:23:11Z","timestamp":1788434591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancerdiagnosisprognosis.org\/article\/654\/real-world-outcomes-of-first-line-platinum-based-chemotherapy-in-patients-aged-80-years-or-older-with-metastatic-urothelial-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.21873\/cdp.10589","relation":{},"ISSN":["2732-7787"],"issn-type":[{"value":"2732-7787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}